Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis
Purpose: Short acting b2 agonists are recommended to be used ≤ 2 canisters per year. It is suggested that overuse of b2 agonists will lead to increased morbidity and mortality. This study aimed to determine if overuse of b2 agonists result in increased morbidity and mortality. Methods: We performe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Journal of Pharmacy & Pharmaceutical Sciences |
| Online Access: | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32738 |
| _version_ | 1827163743757271040 |
|---|---|
| author | Yiyun Hu Janice Kung Dimitri Galatis Hoan Linh Banh |
| author_facet | Yiyun Hu Janice Kung Dimitri Galatis Hoan Linh Banh |
| author_sort | Yiyun Hu |
| collection | DOAJ |
| description |
Purpose: Short acting b2 agonists are recommended to be used ≤ 2 canisters per year. It is suggested that overuse of b2 agonists will lead to increased morbidity and mortality. This study aimed to determine if overuse of b2 agonists result in increased morbidity and mortality. Methods: We performed a systematic review and meta-analysis of the literature to determine if overuse of b2 agonists cause increase mortality, ICU admissions, hospitalization, and exacerbation. Results: A total of 11,888 publications were identified and 4260 duplications were removed, resulting in 7268 abstracts that were screened and 7254 irrelevant studies that were excluded. Ultimately, 14 studies were included. The overall pooled estimated odds ratio (OR) for mortality was 0.83 (95% CI: 0.66, 1.05), 0.99 for ICU admission (95% CI: 0.80, 1.21), 1.22 for hospitalization (95% CI: 0.96, 1.31), and 0.99 for exacerbation (95% CI: 0.85, 1.15). Conclusion: There is no statistical difference in mortality, ICU admission rate, hospitalization, or exacerbation with using b2 agonists.
|
| first_indexed | 2024-03-12T18:08:02Z |
| format | Article |
| id | doaj.art-12d2466f3b3947318fd37aea39d9fe8a |
| institution | Directory Open Access Journal |
| issn | 1482-1826 |
| language | English |
| last_indexed | 2025-03-21T01:05:34Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Journal of Pharmacy & Pharmaceutical Sciences |
| spelling | doaj.art-12d2466f3b3947318fd37aea39d9fe8a2024-08-03T03:34:42ZengFrontiers Media S.A.Journal of Pharmacy & Pharmaceutical Sciences1482-18262022-06-012510.18433/jpps32738Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-AnalysisYiyun Hu0Janice Kung1Dimitri Galatis2Hoan Linh Banh3Second Xiangya Hospital of Central South UniversityUniversity of Alberta, John W. Scott Health Sciences LibraryUniversity of Alberta, Faculty of Pharmacy and Pharmaceutical SciencesUniversity of Alberta Purpose: Short acting b2 agonists are recommended to be used ≤ 2 canisters per year. It is suggested that overuse of b2 agonists will lead to increased morbidity and mortality. This study aimed to determine if overuse of b2 agonists result in increased morbidity and mortality. Methods: We performed a systematic review and meta-analysis of the literature to determine if overuse of b2 agonists cause increase mortality, ICU admissions, hospitalization, and exacerbation. Results: A total of 11,888 publications were identified and 4260 duplications were removed, resulting in 7268 abstracts that were screened and 7254 irrelevant studies that were excluded. Ultimately, 14 studies were included. The overall pooled estimated odds ratio (OR) for mortality was 0.83 (95% CI: 0.66, 1.05), 0.99 for ICU admission (95% CI: 0.80, 1.21), 1.22 for hospitalization (95% CI: 0.96, 1.31), and 0.99 for exacerbation (95% CI: 0.85, 1.15). Conclusion: There is no statistical difference in mortality, ICU admission rate, hospitalization, or exacerbation with using b2 agonists. https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32738 |
| spellingShingle | Yiyun Hu Janice Kung Dimitri Galatis Hoan Linh Banh Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis Journal of Pharmacy & Pharmaceutical Sciences |
| title | Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis |
| title_full | Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis |
| title_fullStr | Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis |
| title_short | Short Acting Beta Agonist Use Associated with Increased Mortality and Morbidity in Asthma Patients: A Systematic Review and Meta-Analysis |
| title_sort | short acting beta agonist use associated with increased mortality and morbidity in asthma patients a systematic review and meta analysis |
| url | https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/32738 |
| work_keys_str_mv | AT yiyunhu shortactingbetaagonistuseassociatedwithincreasedmortalityandmorbidityinasthmapatientsasystematicreviewandmetaanalysis AT janicekung shortactingbetaagonistuseassociatedwithincreasedmortalityandmorbidityinasthmapatientsasystematicreviewandmetaanalysis AT dimitrigalatis shortactingbetaagonistuseassociatedwithincreasedmortalityandmorbidityinasthmapatientsasystematicreviewandmetaanalysis AT hoanlinhbanh shortactingbetaagonistuseassociatedwithincreasedmortalityandmorbidityinasthmapatientsasystematicreviewandmetaanalysis |